Therapeutic cancer vaccines have effectively induced durable regressions of premalignant
oncogenic human papilloma virus type 16 (HPV16)–induced anogenital lesions. However …

Despite the tremendous progresses of cancer immunotherapy, its current clinical responses
rate in melanoma remains to be improved. Here, we have reported a skin penetrating …

The approved worldwide use of two messenger RNA (mRNA) vaccines (BNT162b2 and
mRNA-1273) in late 2020 has proven the remarkable success of mRNA therapeutics …

Background Immune checkpoint inhibiting antibodies were introduced into routine clinical
practice for cancer patients. Checkpoint blockade has led to durable remissions in some …

Vaccines are an important tool in the rapidly evolving repertoire of immunotherapies in
oncology. Although cancer vaccines have been investigated for over 30 years, very few …

Chimeric antigen receptor (CAR) T cells are a form of autologous immunotherapy that has
changed the therapeutic landscape of hematologic malignancies. CAR T cell therapy …

Immune profiling in patients with monoclonal gammopathy of undetermined significance
(MGUS), smoldering multiple myeloma (SMM), and multiple myeloma (MM) provides the …

Targeted therapy and immunotherapy in combination is considered the ideal strategy for
treating metastatic cancer, as it can eliminate the primary tumors and induce host immunity …

The introduction of immune checkpoint inhibitors has changed the therapeutic possibilities
for various cancer types. However, despite the success in some entities, a significant fraction …

Tumor vaccines are a promising form of cancer immunotherapy, but difficulties such as neo-
antigen identification, activation of immune cells, and tumor infiltration prevent their clinical …